A UNIQUE VISION ON MASTERING SIRP
A New Way to Change Lives
WE ARE TAKING A NOVEL APPROACH TO TARGETING SIRP
Our mastery of SIRP-directed biology is pointing the way toward breakthrough therapies for immunological diseases and cancer.
The Signal Regulatory Protein (SIRP) family of cell surface receptors consists of several proteins with differing roles across various immune cell types. Our immunology programs take advantage of the differential expression of SIRP proteins on leukocytes, which provides a means to deplete specific immune cell types. In our immuno-oncology platform, we leverage the SIRPα/CD47 immune checkpoint to promote targeted depletion of tumor cells.
We are embracing the endless possibilities of SIRP biology and
TRANSFORMING THE TREATMENT LANDSCAPE FOR PATIENTS MOST IN NEED.
SIRP-DIRECTED ANTIBODIES
IN DEVELOPMENT
Our novel monoclonal antibodies are designed to change the lives of patients with immunological diseases and cancer.
THE INNOVATIVE TEAM AT
ELECTRA THERAPEUTICS
Our team expands the possibilities of science to create transformative therapies for patients in need.
COLLECTIVELY EXPANDING
THE POSSIBILITIES
Electra Therapeutics is a part of a constellation of companies led by Star Therapeutics, which focuses on developing life-changing therapies for patients with rare diseases.
